Please join us at one of our regular meetings or join the mailing list for our free monthly newsletter. Family members and friends are encouraged to participate as well. You will quickly find out you are not alone. We will help keep you informed of the latest Multiple Myeloma management information.

Next Meeting

The next meeting will be on Tuesday October15, 2019
3:30 PM – 5:30 PM

Dr. Natalie Callander will likely join us for the October meeting. She will be here at 4:30pm to present information from the many conferences that she attends. There will be time for Q & A.

Current newsletter, (PDF)

Upcoming Meeting Speakers…

• Dr. Shannon O'Mahar will be our featured speaker for the December meeting. She will likely be presenting 2019 ASH conference highlights.

From the IMF website....
Multiple myeloma drugs fall into various drug classes, proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).

https://www.myeloma.org/multiple-myeloma-drugs

The PROMISE Study

The PROMISE Study is a collaborative research project screening individuals at higher risk for multiple myeloma.

The PROMISE Study Brochure (PDF)

New Fact Sheet Available from LLS

This new fact sheet provides information for patients and their families about minimal residual disease (MRD), which refers to the small number of cancer cells that remain in the body after treatment.

Click here to download the PDF or order a free copy.

From the LLS Patient Education Team

Conferences

None currently listed

Upcoming Teleconferences or Webinars 

The next “Living Well with Myeloma” Teleconference will focus on approaches to relapsed myeloma. IMF Chairman of the Board Dr. Brian G.M. Durie will discuss:

• What treatments you should consider if your myeloma has relapsed, with a focus on the latest FDA-approved drugs.
• How to individualize treatment based on a patient’s prior therapies, the length of the onset of relapse, FiSH genetic-risk status, age, and frailty score.
• The latest clinical trials, in particular immune therapies.

Thursday, October 10, 2019
6PM Central Time
Duration: 60 Minutes (Includes Q&A)
Click here to register

Multiple Myeloma or Cancer News

News... (Upcoming teleconferences are listed below)

Brand new booklet from the IMF Educational Series.... Understanding Peripheral Neuropathy in Myeloma. This can be viewed online and is very well written. Very comprehensive and will expand what you may already know about this subject. Bet you didn't know about “Pickle Juice”? See page
13.

Our group member, Bashir Nasserjah will be doing “The Ride”, Sunday, September 22, 2019 Madison, WI. To support him and all the riders, go to www.theridewi.org. This ride fundraiser will support the cancer research at the UW-Madison.

Our group member, Georgia passes along this information about a class that she has joined.

I have just started a “Strong Bone” class and I love it! It meets at our village hall in McFarland. It really works ALL of your muscles and is good for balance. The leader had a change in her bone density and started this class. It is actually fun and it is for men and women. There is music and laughter and so much easier to exercise with others. The hour goes by quickly and it's a good feeling mentally. I had tried it out before transplant with another instructor and loved it. After transplant, still love it! Highly recommend it to all.

ChemioCare Developing New Lenalidomide Skin Patch

Attached to the January email: Time to talk about Multiple Myeloma

Please see the December, 2018 newsletter for news about approval of a new drug therapy (EPd) for treatment of relapsed or refractory myeloma in patients who have received at least two prior therapies

MMRF introduces MyDRUG (Myeloma – Developing Regimens Using Genomics) clinical trial. (More in the December, 2018 newsletter)

Success and Celebrations

Matt Howard took first place in the Driftless 50K Trail Race.

Bashir Nasserjah participated in "The Ride", benefiting The UW Carbone Cancer Center.